Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXIS: Axitinib vs Sorafenib in Second-Line mRCC
NCT00678392Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2008
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of axitinib in renal cell carcinoma (RCC) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival up to 3 years. Started Sep 2008; status: completed.
02
Drugs
axitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00678392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00678392.